Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05978011
Other study ID # 2014TP001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 29, 2014
Est. completion date April 4, 2019

Study information

Verified date July 2023
Source Manchester University NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Respiratory diseases are very common and are the third leading cause of death in England. As such, there is strong interest in understanding how respiratory disease occurs. This study intends to understand the changes that occur within diseased/injured lungs obtained from humans. The end goal of this will be to create new drugs to help treat these disorders. Diseased lungs will be obtained from patients receiving a lung transplant. Lungs will either be placed onto a heart-lung machine, or surgically cut in order to create a model of the lung that can be used experimentally in the laboratory. Using a heart-lung machine, lungs can be maintained outside of the human body for a maximum of 12 hours, allowing the direct assessment of the organ. Using this procedure, we aim to understand the processes that occur within a disease, as well as during repair. Using the model of the lung, we will look at how the body's immune system interacts within a diseased lung.


Recruitment information / eligibility

Status Completed
Enrollment 119
Est. completion date April 4, 2019
Est. primary completion date April 4, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients must be able to provide informed consent - Patients must be aged between 18-80 years of age Exclusion Criteria: -Patients under 16 or over 70 years of age

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Manchester University NHS Foundation Trust

Outcome

Type Measure Description Time frame Safety issue
Primary To identify the mechanisms that occur during lung inflammation, injury and repair and the contribution of immune cells to these processes. Cytokines and chemokines within lungs will be assessed to determine inflammatory profiles. This will be done using luminex arrays that allow quantification of a range of immunologic molecules in bronchoalveolar lavage and perfusate samples. This will provide a broad overview of the prevailing local tissue environment. We will also assess this following immunomodulation as this may be significantly altered by the presence of immunomodulatory therapeutics. Prior to lung transplantation.
Secondary Characterise the migration and functional profile of immune cells within the inflamed/damaged lung. Immune cells obtained from the lungs on the EVLP circuit and cells cultured in the air liquid model will be incubated with antibodies that target specific cellular markers for the detection using flow cytometry. Immune cells can then be characterised and their function determined. The behavioural characteristics and activation status of immune cells will also be determined using flow cytometry, ELISpot/ELISA, immunohistochemistry and qPCR. Prior to lung transplantation
Secondary Assess the effectiveness of therapeutic agents that can repair lung damage. Diseased lungs that have been removed from patients during their transplantation will be used as a model to explore novel therapeutic interventions that can modulate inflammation and induce tissue remodelling within the lungs. The entire lungs will be placed within the EVLP circuit and perfused with an acellular solution. Different therapeutic agents will be introduced to the lungs during EVLP and lung function will be monitored. We will determine if lungs have improved via a clinically relevant improvement in lung function (this is the international standard for lung function assessment during EVLP). Prior to lung transplantation
Secondary Trial therapeutic agents that can modulate the effect of immune cells in response to lung tissue injury. Diseased lungs that have been removed from patients during their transplantation will be used as a model to explore novel therapeutic interventions that can modulate inflammation and induce tissue remodelling within the lungs. The entire lungs will be placed within the EVLP circuit and perfused with an acellular solution. Different therapeutic agents will be introduced to the lungs during EVLP and lung function will be monitored. We will determine if lungs have improved via a clinically relevant improvement in lung function (this is the international standard for lung function assessment during EVLP). Prior to lung transplantation
Secondary Identify new therapeutic targets/agents that can reduce the incidence/severity of inflammatory respiratory conditions. PDiseased lungs that have been removed from patients during their transplantation will be used as a model to explore novel therapeutic interventions that can modulate inflammation and induce tissue remodelling within the lungs. The entire lungs will be placed within the EVLP circuit and perfused with an acellular solution. Different therapeutic agents will be introduced to the lungs during EVLP and lung function will be monitored. We will determine if lungs have improved via a clinically relevant improvement in lung function (this is the international standard for lung function assessment during EVLP). Prior to lung transplantation
Secondary Cut sections of the lung to culture in an in vitro lung model to assess the effect of various different mechanisms of injury on the function and characteristics of immune cells. Lungs will be dissected to be used in an in vitro model, generating a morphologically accurate model of the lung. This model will then be used to assess immune cell characteristics. Prior to lung transplantation
See also
  Status Clinical Trial Phase
Recruiting NCT04461821 - Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents
Recruiting NCT06267859 - Development of Methods for Effective Treatment and Improvement of Common Somatic Diseases in Children Early Phase 1
Completed NCT04386408 - Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections Phase 1
Recruiting NCT06229613 - Exhaled Breath Aerosol for the Etiological Diagnosis of Respiratory Tract Infections: a Pilot Study
Completed NCT02084043 - In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation N/A
Completed NCT01113255 - Validation of a Simulated Clinical Evaluation of Ventilators Phase 2/Phase 3
Completed NCT00988000 - Initial Specialist Telephone Consultation With New Patients in Secondary Care N/A
Completed NCT06454513 - Efficacy of Different Anesthesia Methods in Transbronchial Biopsy
Completed NCT02723890 - The Efficacy and Safety of Using the Novel Tyto Device N/A
Completed NCT00719784 - Vibration Response Imaging in the Diagnosis of Pulmonary Disease N/A
Completed NCT00823056 - The Effect of Probiotics on Infections in Toddlers Phase 3
Recruiting NCT06366113 - Time of Exercise Re-training With Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT05175313 - Transthoracic Ultrasonography Findings and Their Relation to Spirometric Indices in Patients With Obstructive and Restrictive Respiratory Diseases
Completed NCT02754947 - Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care
Completed NCT01255592 - Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis Phase 2
Completed NCT00840723 - Bronchoscopy Assisted Sampling of Cells and Fluid From the Lower Respiratory Tract of Human Subjects N/A
Recruiting NCT02717650 - The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. N/A
Completed NCT01196533 - A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters N/A
Completed NCT02406053 - Oxidative Damage and Antioxidant Mechanisms in COPD N/A
Completed NCT01734629 - Pulmonary Disease in Patients Referred for Coronary CT N/A